{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:24:37Z","timestamp":1782797077302,"version":"3.54.5"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The National Cancer Center Research and Development Fund","award":["2022-A-15"],"award-info":[{"award-number":["2022-A-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>eribulin, an anticancer agent that inhibits microtubule growth, along with trabectedin and pazopanib, has been approved for the treatment of advanced soft tissue sarcoma (STS). However, there has been no consensus on the optimal second-line therapy among these three agents following treatment failure with doxorubicin. Recently, the effects of eribulin on the tumor microenvironment and immunity have been reported in breast cancer, and peripheral blood immune markers have also been reported to be a predictor of eribulin efficacy, though this remains unverified in STS. We aimed to evaluate the predictive value of various peripheral blood immune markers in STS patients treated with eribulin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>we retrospectively reviewed the medical records of STS patients treated with eribulin and examined whether peripheral blood immune markers at different time points could be prognostic factors for STS patients treated with eribulin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>several peripheral blood immune markers were significantly associated with progression-free survival (PFS), specifically neutrophil-to-lymphocyte ratio (NLR) prestart (NLR before the initial administration of eribulin) (P\u00a0=\u00a00.019) and absolute lymphocyte count (ALC)8D (ALC on Day 8 of the first administration of eribulin) (P\u00a0=\u00a00.037). NLR prestart (P\u00a0=\u00a00.001) was significantly associated with overall survival. The combination of NLR prestart and ALC8D determined the PFS of STS patients treated with eribulin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>the combined indicator of low NLR prestart and high ALC8D predicted the survival of patients treated with eribulin as well as the histology of L-sarcoma. Though further validation was needed, this finding would provide valuable prognostic factor that help treatment decision in the absence of consensus on the optimal second-line therapy following doxorubicin treatment in STS patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad021","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T15:59:45Z","timestamp":1680191985000},"page":"494-500","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of peripheral blood markers in soft tissue sarcoma patients treated with eribulin"],"prefix":"10.1093","volume":"53","author":[{"given":"Shin","family":"Ishihara","sequence":"first","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Ogura","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiko","family":"Maejima","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Medical Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Medical Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Medical Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Medical Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Fukushima","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Osaki","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Iwata","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Urology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Medical Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital Department of Musculoskeletal Oncology, , Chuo-ku, Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"2023060113502960800_ref1","volume-title":"World Health Organization Classification of Soft Tissue and Bone Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020","edition":"5th"},{"key":"2023060113502960800_ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051086","article-title":"Role of tumor-associated macrophages in sarcomas","volume":"13","author":"Fujiwara","year":"2021","journal-title":"Cancers"},{"key":"2023060113502960800_ref3","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10214972","article-title":"Does the use of peripheral immune-related markers indicate whether to administer pazopanib, trabectedin, or eribulin to advanced soft tissue sarcoma patients?","volume":"10","author":"Shimada","year":"2021","journal-title":"J Clin Med"},{"key":"2023060113502960800_ref4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"2023060113502960800_ref5","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-14-3252","article-title":"Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent","volume":"21","author":"Dybdal-Hargreaves","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023060113502960800_ref6","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"2023060113502960800_ref7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s12282-020-01067-2","article-title":"High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician\u2019s choice-in the EMBRACE study","volume":"27","author":"Miyoshi","year":"2020","journal-title":"Breast Cancer"},{"key":"2023060113502960800_ref8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2023060113502960800_ref9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.21873\/anticanres.14804","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio predicts efficacy of eribulin for soft-tissue sarcoma","volume":"41","author":"Sato","year":"2021","journal-title":"Anticancer Res"},{"key":"2023060113502960800_ref10","doi-asserted-by":"crossref","first-page":"e210845","DOI":"10.1001\/jamanetworkopen.2021.0845","article-title":"Evaluation of absolute lymphocyte count at diagnosis and mortality among patients with localized bone or soft tissue sarcoma","volume":"4","author":"Brewster","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023060113502960800_ref11","doi-asserted-by":"crossref","first-page":"8839512","DOI":"10.1155\/2021\/8839512","article-title":"Prognostic value of Pretreated blood inflammatory markers in patients with bone sarcoma: a meta-analysis","volume":"2021","author":"Jiang","year":"2021","journal-title":"Dis Markers"},{"key":"2023060113502960800_ref12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246266","article-title":"Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of Pazopanib treatment for soft-tissue sarcoma","volume":"13","author":"Sato","year":"2021","journal-title":"Cancers"},{"key":"2023060113502960800_ref13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-19-0358","article-title":"Eribulin suppresses clear cell sarcoma growth by inhibiting cell proliferation and inducing melanocytic differentiation both directly and via vascular remodeling","volume":"19","author":"Nakai","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2023060113502960800_ref14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbrc.2021.07.033","article-title":"Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model","volume":"570","author":"Taguchi","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2023060113502960800_ref15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/ijc.10343","article-title":"Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma","volume":"99","author":"Nakanishi","year":"2002","journal-title":"Int J Cancer"},{"key":"2023060113502960800_ref16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.arr.2009.03.004","article-title":"The role of epigenetics in aging and age-related diseases","volume":"8","author":"Calvanese","year":"2009","journal-title":"Ageing Res Rev"},{"key":"2023060113502960800_ref17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41586-020-2394-6","article-title":"DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25","volume":"583","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"2023060113502960800_ref18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174495","article-title":"Neutrophil extracellular traps (NETs) in cancer invasion, evasion and metastasis","volume":"13","author":"Demkow","year":"2021","journal-title":"Cancers"},{"key":"2023060113502960800_ref19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2020.00030","article-title":"Meta-analysis of Hematological biomarkers as reliable indicators of soft tissue sarcoma prognosis","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/6\/494\/50501069\/hyad021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/53\/6\/494\/50501069\/hyad021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T13:53:18Z","timestamp":1685627598000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/53\/6\/494\/7093188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,30]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad021","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,30]]}}}